UY29921A1 - Derivados de 3-acilindol, su preparación y su aplicación en terapéutica - Google Patents

Derivados de 3-acilindol, su preparación y su aplicación en terapéutica

Info

Publication number
UY29921A1
UY29921A1 UY29921A UY29921A UY29921A1 UY 29921 A1 UY29921 A1 UY 29921A1 UY 29921 A UY29921 A UY 29921A UY 29921 A UY29921 A UY 29921A UY 29921 A1 UY29921 A1 UY 29921A1
Authority
UY
Uruguay
Prior art keywords
preparation
acilindol
therapeutics
derivatives
application
Prior art date
Application number
UY29921A
Other languages
English (en)
Inventor
Guillaumont-Legeay Carole
Rinaldi-Carmona Murielle
Barth Francis
Vernhet Claude
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36619225&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29921(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY29921A1 publication Critical patent/UY29921A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Se divulgan compuestos derivados de 3-acilindol de la fórmula (I) en la que los radicales, índices y sustituyentes tienen el significado especificado en la Memoria Descriptivas y en las Reivindicaciones. Redivulga el proceso de preparación y las aplicaciones terapéuticas.
UY29921A 2005-11-18 2006-11-17 Derivados de 3-acilindol, su preparación y su aplicación en terapéutica UY29921A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0511740A FR2893615B1 (fr) 2005-11-18 2005-11-18 Derives de 3-acylindole, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
UY29921A1 true UY29921A1 (es) 2007-06-29

Family

ID=36619225

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29921A UY29921A1 (es) 2005-11-18 2006-11-17 Derivados de 3-acilindol, su preparación y su aplicación en terapéutica

Country Status (9)

Country Link
US (1) US7741363B2 (es)
EP (1) EP1951225B1 (es)
JP (1) JP5106410B2 (es)
AR (1) AR057898A1 (es)
AT (1) ATE543496T1 (es)
FR (1) FR2893615B1 (es)
TW (1) TW200738628A (es)
UY (1) UY29921A1 (es)
WO (1) WO2007057571A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2950055A1 (fr) 2009-09-17 2011-03-18 Sanofi Aventis Derives de 3-amino-cinnolin-4(1h)-one substitues, leur preparation et leur application en therapeutique
FR2983859B1 (fr) 2011-12-12 2014-01-17 Sanofi Sa Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique
EP4253396A1 (en) * 2020-11-27 2023-10-04 Mirailab Bioscience Inc. High-purity beta-nicotinamide mononucleotide (nmn) and method for producing same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581354A (en) 1984-08-06 1986-04-08 Sterling Drug Inc. 3-arylcarbonyl- and 3-cycloalkylcarbonyl-1-aminoalkyl-1H-indoles, compositions and use
CA2036307C (en) * 1990-03-08 2002-07-09 Susan Jean Ward 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions and method
GB9115951D0 (en) * 1991-07-24 1991-09-11 Pfizer Ltd Indoles
US5532237A (en) * 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
FR2735774B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
FR2816938B1 (fr) * 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
DE60237431D1 (de) * 2001-01-29 2010-10-07 Univ Connecticut Rezeptor-selektive cannabimimetische aminoalkylindole
FR2839718B1 (fr) * 2002-05-17 2004-06-25 Sanofi Synthelabo Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant
FR2847899B1 (fr) * 2002-11-29 2006-04-28 Sanofi Synthelabo Derives d'indole-3-carboxamide, leur preparation et leur application en therapeutique
WO2005056522A2 (en) * 2003-12-04 2005-06-23 National Health Research Institutes Indole compounds
TW200522944A (en) * 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
US7560481B2 (en) * 2004-12-21 2009-07-14 Abbott Laboratories Indoles are cannabinoid receptor ligands

Also Published As

Publication number Publication date
EP1951225B1 (fr) 2012-02-01
US7741363B2 (en) 2010-06-22
TW200738628A (en) 2007-10-16
WO2007057571A2 (fr) 2007-05-24
ATE543496T1 (de) 2012-02-15
US20080275102A1 (en) 2008-11-06
WO2007057571A3 (fr) 2007-07-12
JP5106410B2 (ja) 2012-12-26
JP2009515935A (ja) 2009-04-16
FR2893615B1 (fr) 2008-03-07
FR2893615A1 (fr) 2007-05-25
AR057898A1 (es) 2007-12-26
EP1951225A2 (fr) 2008-08-06

Similar Documents

Publication Publication Date Title
CY1119669T1 (el) Παραγωγα 1-φαινυλ-2-πυριδινυλ-αλκυλ-αλκοολων ως αναστολεις φωσφοδιεστερασης
UY29518A1 (es) Derivados de alquil-, alquenil- y alquinilcarbamatos, su preparación y su aplicación en terapéutica.
UY31037A1 (es) Derivados de triazolopiridin-carboxamidas, su preparacion y su aplicacion en terapeutica
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
ECSP10010722A (es) Compuestos orgánicos
UY30500A1 (es) Compuestos de azabencimidazolilo
EA201100875A1 (ru) Новые пиразол-4-n-алкоксикарбоксамиды в качестве микробиоцидов
EA201790678A1 (ru) Бициклические гетероарильные соединения
EA201000395A1 (ru) Фунгицидные производные 2-алкилтио-2-хинолинилоксиацетамида
UY31166A1 (es) Nuevos indazoles sustituidos, su preparación y su utilización en terapeutica
UY31032A1 (es) Derivados de triazolopiridin-carboxamidas y triazolopirimidin-carboxinamidas, su preparacion y su aplicacion en terapeutica
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
EA200802213A1 (ru) Способы лечения заболеваний крови
HN2012001162A (es) Triazolopiridinas
UY29690A1 (es) Derivados de n-(heteroaril)-1-heteroarilalquil-1h-indol-2-carboxamidas, su preparación y su aplicación en terapéutica.
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
UY31236A1 (es) Derivados de la 6-cicloamino-3-(piridazin-4-il)imidazo[1,2-b]-piridazina, su preparacion y su aplicacion en terapéutica
CR8744A (es) Compuestos terapeuticos
EA201000777A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
UA109775C2 (xx) N-вмісні гетероарильні похідні як інгібітори jak3-кінази
UY29414A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
MA32544B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
UY31689A1 (es) Derivados de platino-carbeno n-heterocíclico, su preparación y su aplicación en terapéutica
CR20140135A (es) Nuevos derivados de aril-quinolina

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120515